PFE · News · 20260914N

Guidance and Outlook

PFIZER INC · 2026-09-14 · Importance 31 · Surprise 42

Third-party reporting says Pfizer expects new products, acquisitions, and its pipeline to support growth from 2029. The outlook is driven by oncology and obesity programs, including GLP-1 therapies, while COVID-19 revenue declines and patent cliffs remain headwinds. Management reportedly said major headwinds are easing and that investor attention is shifting toward future pipeline growth, but no quantified revenue, margin, or capital-expenditure guidance was provided.

Key facts

• A news article stated that Pfizer's new products, acquisitions and a strong pipeline could fuel growth from 2029. source
• Pfizer presented at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, at 10:45 AM. source
• A report said Pfizer exceeded revenue and earnings despite lower COVID-19 demand. source